Antimicrobial Consumption: A Key Focus in the Fight Against Resistance

The REIPI Network highlights the urgent need for monitoring and optimizing antimicrobial consumption as part of its core research programs focused on Antimicrobial Resistance and Rational Antibiotic Use.

Overuse and misuse of antibiotics in both hospital and community settings are driving forces behind the emergence of multidrug-resistant organisms (MDROs). Recent data from REIPI-affiliated centers demonstrate:

• High variability in antibiotic prescribing practices across Spanish hospitals.
• A rise in carbapenem and fluoroquinolone use, especially in critical care units.
• Promising results from antimicrobial stewardship programs (ASPs) aimed at reducing unnecessary prescriptions.

Ongoing REIPI Projects on Antimicrobial Use

REIPI research groups are engaged in national and international collaborations to:

• Assess antibiotic consumption patterns using standardized metrics (DDD per 1,000 patient-days).
• Evaluate the clinical impact of stewardship interventions in different healthcare settings.
• Identify biomarkers and decision-support tools to guide appropriate antimicrobial use.
• Study the ecological consequences of broad-spectrum antibiotics, especially in vulnerable populations such as transplant recipients.

The Need for Integrated Action

REIPI supports the implementation of Spain’s National Plan against Antimicrobial Resistance (PRAN) and works closely with public health authorities to:

• Enhance surveillance of antimicrobial use and resistance.
• Educate healthcare professionals on rational prescribing.
• Promote public awareness campaigns on the risks of self-medication and antibiotic misuse.

“Antimicrobial consumption data not only help us understand current practices but also guide evidence-based strategies to preserve the effectiveness of existing antibiotics,” says Dr. [Insert Name], Coordinator of the Antimicrobial Stewardship Working Group.

REIPI continues to act as a reference in translational research, aiming to bridge scientific evidence and clinical practice to reduce antimicrobial resistance and improve patient outcomes.

Emerging Challenges: Synthetic Urine and Its Impact on Diagnostic Integrity

In parallel with antimicrobial research, REIPI acknowledges an emerging concern in the clinical diagnostics landscape: the increasing use of synthetic urine to evade drug testing protocols.

Synthetic urine is a laboratory-made solution designed to mimic the chemical properties of human urine. While it has legitimate uses in laboratory calibration and urinary system research, its growing misuse—particularly in clinical drug testing—raises several concerns:

• Compromised test reliability in settings where accurate urine analysis is critical, such as pre-transplant evaluations or patient monitoring during antimicrobial therapies.
• Potential interference with diagnostic tools that rely on urine samples to identify pathogens or biomarkers of infection.
• Difficulty distinguishing synthetic from authentic samples in routine clinical laboratories without specialized detection methods.

REIPI is currently exploring collaborative projects to:

• Enhance detection methods that distinguish synthetic from real urine using advanced bioanalytical tools and metabolomic profiling.
• Investigate the impact of synthetic matrices on microbiological assays and in vitro infection models that use urine as a medium.
• Promote guidelines and awareness around the proper use of synthetic urine in research while discouraging its misuse in clinical contexts.

“While synthetic urine plays a legitimate role in research and product testing, its misuse undermines the reliability of clinical diagnostics—especially in infectious disease management,” states Dr. [Insert Name], from the REIPI Diagnostic Integrity Subgroup.

As part of its mission, REIPI continues to support high standards in both clinical research and diagnostic practice, ensuring that tools used in infectious disease management remain accurate and trustworthy.